Literature DB >> 11716891

Zambian women's attitudes toward mass nevirapine therapy to prevent perinatal transmission of HIV.

M Sinkala, J P Stout, S H Vermund, R L Goldenberg, J S Stringer.   

Abstract

Use of mass nevirapine therapy--universal provision of the drug without HIV testing--for prevention of perinatal HIV in high prevalence settings with extreme resource constraints is a controversial strategy. A quarter of pregnant Zambian women surveyed would prefer to receive nevirapine through a non-testing mass strategy, and most would support mass therapy as a policy if it would make the drug available to a larger proportion of the at-risk population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716891     DOI: 10.1016/S0140-6736(01)06662-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

Review 1.  Role of traditional birth attendants in preventing perinatal transmission of HIV.

Authors:  Marc Bulterys; Mary Glenn Fowler; Nathan Shaffer; Pius M Tih; Alan E Greenberg; Etienne Karita; Hoosen Coovadia; Kevin M De Cock
Journal:  BMJ       Date:  2002-01-26

2.  Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings.

Authors:  Jeffrey S A Stringer; Moses Sinkala; Julia P Stout; Robert L Goldenberg; Edward P Acosta; Victoria Chapman; Rosemary Kumwenda-Phiri; Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-15       Impact factor: 3.731

Review 3.  Tackling HIV through robust diagnostics in the developing world: current status and future opportunities.

Authors:  Darash Desai; Grace Wu; Muhammad H Zaman
Journal:  Lab Chip       Date:  2010-12-01       Impact factor: 6.799

4.  Personal risk perception, HIV knowledge and risk avoidance behavior, and their relationships to actual HIV serostatus in an urban African obstetric population.

Authors:  Elizabeth M Stringer; Moses Sinkala; Rosemary Kumwenda; Victoria Chapman; Alexandrina Mwale; Sten H Vermund; Robert L Goldenberg; Jeffrey S A Stringer
Journal:  J Acquir Immune Defic Syndr       Date:  2004-01-01       Impact factor: 3.731

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.